Viewing nowCozaar (Losartan Potassium)
Losartan Potassium 50mg
Tablet · Prescription medication
Korea Organon Co., Ltd.

MFDS item code 200811814 · Approved 2008.12.23 · Insurance code 073100220
Treatment of hypertension; prevention of stroke in hypertension with left ventricular hypertrophy; treatment of diabetic nephropathy in type 2 diabetes
This medication is used to control blood pressure in patients with hypertension, particularly helping to reduce the risk of stroke in hypertensive patients with left ventricular hypertrophy. It is also effective in preventing the progression of kidney complications in patients with type 2 diabetes and hypertension. Therefore, it is used to improve various complications associated with hypertension.
This medicine may be taken with or without food, but it is recommended that it be taken at the same time each day. 1. Hypertension 1) Adults The recommended initial and maintenance dose is 50 mg of losartan potassium orally once daily. The maximum blood pressure-lowering effect is achieved 3 ∼ 6 weeks after starting treatment. If the therapeutic effect is insufficient, the same dose may be administered orally in 2 divided doses daily or, if necessary, increased to 100 mg once daily. 3) If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with another antihypertensive agent (e.g., a low-dose diuretic). An additive effect has been observed with concomitant administration of hydrochlorothiazide. 2. Reduction in the risk of stroke in hypertensive patients with left ventricular hypertrophy The usual initial dose in adults is 50 mg of this medicine once daily. Depending on blood pressure, hydrochlorothiazide 12.5 mg once daily may be added and/or the dose of this medicine may be increased to 100 mg once daily. If additional blood pressure reduction is required, hydrochlorothiazide may be increased to 25 mg once daily. 3. Nephropathy in patients with type 2 diabetes and hypertension The usual dose in adults is 50 mg of this medicine once daily. Depending on blood pressure, the dose may be increased to 100 mg once daily. However, an initial dose of 25 mg is recommended for patients at risk of excessive blood pressure reduction. This medicine may be administered concomitantly with insulin and commonly used glucose-lowering agents (e.g., sulfonylureas, glitazones, and glucosidase inhibitors). 4. Special patient populations 1) Elderly patients No adjustment of the initial dose is required in elderly patients aged 75 years or younger. For elderly patients over 75 years of age, an initial dose of 25 mg of this medicine once daily is recommended. 2) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No adjustment of the initial dose is required. (2) Creatinine clearance < 20 mL/min and patients on dialysis: An initial dose of 25 mg of this medicine once daily is recommended. 3) Patients with reduced intravascular effective circulating volume For patients who may have reduced intravascular effective circulating volume (e.g., patients being treated with diuretics), an initial dose of 25 mg of this medicine once daily is recommended (see Precautions for Use). 4) Patients with hepatic impairment A lower dose should be considered in patients with a history of hepatic impairment. Do not administer to patients with severe hepatic impairment.
Pediatric and adolescent patients 6 years of age or older who weigh 20 kg or more but less than 50 kg and are able to swallow tablets: The recommended dose is 25 mg of this medicine once daily; the dose may be increased to a maximum of 50 mg once daily, depending on the patient's blood pressure response. Pediatric and adolescent patients 6 years of age or older who weigh 50 kg or more: The usual recommended dose is 50 mg of this medicine once daily; the dose may be increased to a maximum of 100 mg once daily, depending on the patient's blood pressure response. This medicine is not recommended for pediatric patients under 6 years of age, pediatric patients with a glomerular filtration rate below 30 mL/min/1.73㎡, or pediatric patients with hepatic impairment.
This medication can cause serious damage to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Using this medication during pregnancy may impair fetal lung development or cause skeletal deformities, and newborns may exhibit issues such as decreased skull formation, kidney failure, and low blood pressure. This medication should not be administered to patients with severely impaired liver or kidney function, patients with certain genetic disorders, or women who are pregnant or may become pregnant. Elderly patients, patients with weakened kidney function, and those with hyperkalemia require special caution when using this medication, and dosage should be gradually increased under medical supervision due to the risk of sudden drops in blood pressure. Side effects such as dizziness, muscle cramps, low back pain, respiratory infections, and others may occur, and rare severe reactions such as angioedema, liver dysfunction, or serious muscle damage can arise; any unusual symptoms should be reported to medical personnel immediately. This medication should be avoided when taken with other antihypertensive medications, potassium-sparing diuretics, or potassium supplements due to the risk of elevated potassium levels, and co-administration with non-steroidal anti-inflammatory drugs may reduce blood-pressure-lowering efficacy or worsen kidney function. It is important to regularly monitor blood pressure and blood tests, especially kidney function and serum potassium levels, during the administration of this medication. Women who are pregnant or planning to become pregnant should consult with a physician, and it is advisable to avoid this medication while breastfeeding. This medication is not administered to children, especially those under 6 years of age or those with severe kidney dysfunction. In case of overdose, hypotension and cardiac arrhythmias may occur, and appropriate medical treatment should be sought immediately. Store this medication out of reach of children and avoid transferring to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, the medication should be kept at a cool room temperature, ideally between 1 and 30 degrees Celsius.
White oval film-coated tablet engraved with 952 on one side
30 tablets (15 tablets/PTP x 2), 300 tablets (300 tablets/bottle)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowLosartan Potassium 50mg
Tablet · Prescription medication
Korea Organon Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
DaeWon Pharmaceutical Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
Korea United Pharm, Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
HK Inno.N Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
IYON Pharmaceuticals Co., Ltd.
Losartan Potassium
Prescription medication
JW ShinYak Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
Kukje Pharmaceutical Co., Ltd.

Losartan Potassium 50mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.